{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:57:22Z","timestamp":1784833042960,"version":"3.55.0"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Membranous nephropathy (MN) is a common glomerular disease leading to nephrotic syndrome in adults, clinically characterized by massive proteinuria, hypoalbuminemia, and prominent hyperlipidemia. Growing evidence suggests that hyperlipidemia is not merely a secondary consequence of MN, but may also play a critical role in the pathogenesis and progression of MN. This review specifically focuses on hyperlipidemia in MN\u2014rather than nephrotic dyslipidemia in general\u2014to clarify its distinct mechanisms and implications. We examine the association between hyperlipidemia and MN, elucidating the mechanisms from various perspectives including genetic background, the sPLA2-IB\/PLA2R axis, the impact of hyperlipidemia on glomerular podocytes and proximal tubule cells, as well as its modulation of immune function. Therefore, this review aims to critically delineate the specific contributions of hyperlipidemia to MN pathology, distinguishing its active role from passive association, and to evaluate the resulting implications for developing targeted therapeutic interventions.<\/jats:p>","DOI":"10.1093\/ckj\/sfag032","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:34:10Z","timestamp":1770640450000},"source":"Crossref","is-referenced-by-count":2,"title":["Hyperlipidemia in membranous nephropathy"],"prefix":"10.1093","volume":"19","author":[{"given":"Meng","family":"Zhang","sequence":"first","affiliation":[{"name":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Department of Nephrology, , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5478-5444","authenticated-orcid":false,"given":"Wei-lin","family":"Liu","sequence":"additional","affiliation":[{"name":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Department of Nephrology, , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[{"name":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Department of Nephrology, , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dong","sequence":"additional","affiliation":[{"name":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Department of Nephrology, , Wuhan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026031808521417400_bib1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0272-6386(00)70316-7","article-title":"Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia\/New Zealand: results from an international comparative study","volume":"35","author":"Maisonneuve","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"2026031808521417400_bib2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026031808521417400_bib3","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/ndt\/gfx296","article-title":"Genetics of membranous nephropathy","volume":"33","author":"Gupta","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026031808521417400_bib4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.kint.2016.02.026","article-title":"Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences","volume":"90","author":"Vaziri","year":"2016","journal-title":"Kidney Int"},{"key":"2026031808521417400_bib5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026031808521417400_bib6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/biom11040513","article-title":"Mechanisms of primary membranous nephropathy","volume":"11","author":"Gu","year":"2021","journal-title":"Biomolecules"},{"key":"2026031808521417400_bib7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrneph.2012.115","article-title":"Childhood nephrotic syndrome\u2014current and future therapies","volume":"8","author":"Greenbaum","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2026031808521417400_bib8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"Hull","year":"2008","journal-title":"BMJ"},{"key":"2026031808521417400_bib9","doi-asserted-by":"publisher","first-page":"11756","DOI":"10.3390\/ijms241411756","article-title":"Towards the definition of the molecular hallmarks of idiopathic membranous nephropathy in serum proteome: a DIA-PASEF approach","volume":"24","author":"Previtali","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026031808521417400_bib10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1258\/acb.2011.011111","article-title":"Apolipoproteins: metabolic role and clinical biochemistry applications","volume":"48","author":"Dominiczak","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"2026031808521417400_bib11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2026031808521417400_bib12","doi-asserted-by":"publisher","first-page":"e012143","DOI":"10.1161\/JAHA.119.012143","article-title":"Prevalence of cardiovascular disease risk factors in childhood glomerular diseases","volume":"8","author":"Ashoor","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026031808521417400_bib13","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s11255-021-02844-4","article-title":"Hyperuricemia and hypertriglyceridemia indicate tubular atrophy\/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy","volume":"53","author":"Liu","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"2026031808521417400_bib14","doi-asserted-by":"publisher","first-page":"1322646","DOI":"10.3389\/fendo.2024.1322646","article-title":"Defining the threshold: triglyceride to high-density lipoprotein cholesterol (TG\/HDL-C) ratio\u2019s non-linear impact on tubular atrophy in primary membranous nephropathy","volume":"15","author":"Guan","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026031808521417400_bib15","doi-asserted-by":"publisher","first-page":"905930","DOI":"10.3389\/fimmu.2022.905930","article-title":"Hypercholesterolemia correlates with glomerular phospholipase A2 receptor deposit and serum anti-phospholipase A2 receptor antibody and predicts proteinuria outcome in idiopathic membranous nephropathy","volume":"13","author":"Dong","year":"2022","journal-title":"Front Immunol"},{"key":"2026031808521417400_bib16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12944-021-01558-x","article-title":"Utility of non-HDL-C in predicting proteinuria remission of idiopathic membranous nephropathy: a retrospective cohort study","volume":"20","author":"Dong","year":"2021","journal-title":"Lipids Health Dis"},{"key":"2026031808521417400_bib17","doi-asserted-by":"publisher","first-page":"132200","DOI":"10.1016\/j.ijcard.2024.132200","article-title":"Patterns of coronary artery disease trends in patients with nephrotic syndrome: a national inpatient study","volume":"410","author":"Regis","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026031808521417400_bib18","first-page":"1313","article-title":"Lipoproteins accumulate in immune deposits and are modified by lipid peroxidation in passive Heymann nephritis","volume":"149","author":"Exner","year":"1996","journal-title":"Am J Pathol"},{"key":"2026031808521417400_bib19","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1172\/JCI119768","article-title":"Pathogenic antibodies inhibit the binding of apolipoproteins to megalin\/gp330 in passive Heymann nephritis","volume":"100","author":"Kerjaschki","year":"1997","journal-title":"J Clin Invest"},{"key":"2026031808521417400_bib20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.kint.2022.09.008","article-title":"Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice","volume":"103","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"key":"2026031808521417400_bib21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/j.ajkd.2023.05.014","article-title":"Nuclear magnetic resonance-based metabolomics and risk of CKD","volume":"83","author":"Geng","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026031808521417400_bib22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"2026031808521417400_bib23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2215\/CJN.05310513","article-title":"HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy","volume":"9","author":"Bullich","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026031808521417400_bib24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ndt\/gfw001","article-title":"Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies","volume":"32","author":"Sekula","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026031808521417400_bib25","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1681\/ASN.2016020114","article-title":"MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy","volume":"28","author":"Cui","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026031808521417400_bib26","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1681\/ASN.2016060644","article-title":"HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-related membranous nephropathy","volume":"28","author":"Le","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026031808521417400_bib27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1042\/CS20181110","article-title":"Lipid metabolism participates in human membranous nephropathy identified by whole-genome gene expression profiling","volume":"133","author":"Wu","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"2026031808521417400_bib28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2215\/CJN.0000000000000070","article-title":"Kidney disease progression in membranous nephropathy among Black participants with high-risk APOL1 genotype","volume":"18","author":"Chen","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026031808521417400_bib29","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1016\/j.immuni.2021.10.004","article-title":"APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis","volume":"54","author":"Wu","year":"2021","journal-title":"Immunity"},{"key":"2026031808521417400_bib30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136329","article-title":"The key role of NLRP3 and STING in APOL1-associated podocytopathy","volume":"131","author":"Wu","year":"2021","journal-title":"J Clin Invest"},{"key":"2026031808521417400_bib31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0165-6147(99)01300-0","article-title":"Receptors for a growing family of secreted phospholipases A2","volume":"20","author":"Lambeau","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"2026031808521417400_bib32","doi-asserted-by":"publisher","first-page":"8963","DOI":"10.1074\/jbc.270.15.8963","article-title":"The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization","volume":"270","author":"Ancian","year":"1995","journal-title":"J Biol Chem"},{"key":"2026031808521417400_bib33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0090-6980(02)00022-9","article-title":"Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2","volume":"68-69","author":"Hanasaki","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2026031808521417400_bib34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0378-1119(00)00006-8","article-title":"Molecular structure and tissue-specific expression of the mouse pancreatic phospholipase A(2) gene","volume":"244","author":"Richmond","year":"2000","journal-title":"Gene"},{"key":"2026031808521417400_bib35","doi-asserted-by":"publisher","first-page":"11834","DOI":"10.1039\/C6NR03376H","article-title":"Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase","volume":"8","author":"Liu","year":"2016","journal-title":"Nanoscale"},{"key":"2026031808521417400_bib36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000071481","article-title":"Secretory phospholipases A2 as multivalent mediators of inflammatory and allergic disorders","volume":"131","author":"Granata","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"key":"2026031808521417400_bib37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/ijo.2010.215","article-title":"Pancreatic acinar cell-specific overexpression of group 1B phospholipase A2 exacerbates diet-induced obesity and insulin resistance in mice","volume":"35","author":"Cash","year":"2011","journal-title":"Int J Obes"},{"key":"2026031808521417400_bib38","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1194\/jlr.M019463","article-title":"Group 1B phospholipase A(2) deficiency protects against diet-induced hyperlipidemia in mice","volume":"52","author":"Hollie","year":"2011","journal-title":"J Lipid Res"},{"key":"2026031808521417400_bib39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.atherosclerosis.2014.03.027","article-title":"Group 1B phospholipase A(2) inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice","volume":"234","author":"Hollie","year":"2014","journal-title":"Atherosclerosis"},{"key":"2026031808521417400_bib40","first-page":"491","article-title":"Group I and group II phospholipases A2 in serum in uraemia","volume":"31","author":"Peuravuori","year":"1993","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"2026031808521417400_bib41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cca.2018.04.009","article-title":"Serum secretory phospholipase A2 group IB correlates with the severity of membranous nephropathy","volume":"482","author":"Li","year":"2018","journal-title":"Clin Chim Acta"},{"key":"2026031808521417400_bib42","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11596-020-2246-5","article-title":"sPLA2-IB level correlates with hyperlipidemia and the prognosis of idiopathic membranous nephropathy","volume":"40","author":"Yang","year":"2020","journal-title":"Curr Med Sci"},{"key":"2026031808521417400_bib43","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.1038\/srep06660","article-title":"sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor","volume":"4","author":"Pan","year":"2014","journal-title":"Sci Rep"},{"key":"2026031808521417400_bib44","doi-asserted-by":"publisher","first-page":"e21170","DOI":"10.1096\/fj.202001143R","article-title":"sPLA2-IB and PLA2R mediate insufficient autophagy and contribute to podocyte injury in idiopathic membranous nephropathy by activation of the p38MAPK\/mTOR\/ULK1(ser757) signaling pathway","volume":"35","author":"Yang","year":"2021","journal-title":"FASEB J"},{"key":"2026031808521417400_bib45","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s12013-025-01714-5","article-title":"sPLA2-IB and PLA2R mediate aberrant glucose metabolism in podocytes via hyperactivation of the mTOR\/HIF-1alpha pathway","volume":"83","author":"Bao","year":"2025","journal-title":"Cell Biochem Biophys"},{"key":"2026031808521417400_bib46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrneph.2014.87","article-title":"Lipid biology of the podocyte\u2014new perspectives offer new opportunities","volume":"10","author":"Fornoni","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2026031808521417400_bib47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3389\/fphys.2020.00732","article-title":"The vicious cycle of renal lipotoxicity and mitochondrial dysfunction","volume":"11","author":"Ge","year":"2020","journal-title":"Front Physiol"},{"key":"2026031808521417400_bib48","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2337\/db13-0399","article-title":"Cyclodextrin protects podocytes in diabetic kidney disease","volume":"62","author":"Merscher-Gomez","year":"2013","journal-title":"Diabetes"},{"key":"2026031808521417400_bib49","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1172\/JCI85939","article-title":"Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury","volume":"126","author":"Pedigo","year":"2016","journal-title":"J Clin Invest"},{"key":"2026031808521417400_bib50","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.2353\/ajpath.2009.080960","article-title":"CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein","volume":"174","author":"Gutwein","year":"2009","journal-title":"Am J Pathol"},{"key":"2026031808521417400_bib51","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1111\/j.1582-4934.2009.00761.x","article-title":"CXCL16 and oxLDL are induced in the onset of diabetic nephropathy","volume":"13","author":"Gutwein","year":"2009","journal-title":"J Cellular Molecular Medi"},{"key":"2026031808521417400_bib52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cellsig.2018.12.001","article-title":"Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia","volume":"55","author":"Shrestha","year":"2019","journal-title":"Cell Signalling"},{"key":"2026031808521417400_bib53","first-page":"15696","article-title":"Simvastatin ameliorates renal lipidosis through the suppression of renal CXCL16 expression in mice with adriamycin-induced nephropathy","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2026031808521417400_bib54","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s00592-015-0753-9","article-title":"Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy","volume":"52","author":"Zhang","year":"2015","journal-title":"Acta Diabetol"},{"key":"2026031808521417400_bib55","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1172\/JCI125316","article-title":"ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes","volume":"129","author":"Ducasa","year":"2019","journal-title":"J Clin Invest"},{"key":"2026031808521417400_bib56","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000518132","article-title":"The updates of podocyte lipid metabolism in proteinuric kidney disease","volume":"7","author":"Sun","year":"2021","journal-title":"Kidney Dis"},{"key":"2026031808521417400_bib57","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.2337\/diabetes.54.8.2328","article-title":"Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb\/db mice with type 2 diabetes","volume":"54","author":"Wang","year":"2005","journal-title":"Diabetes"},{"key":"2026031808521417400_bib58","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161783","article-title":"Impaired fatty acid metabolism perpetuates lipotoxicity along the transition to chronic kidney injury","volume":"7","author":"Rinaldi","year":"2022","journal-title":"JCI Insight"},{"key":"2026031808521417400_bib59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.kint.2024.02.025","article-title":"The key role of altered tubule cell lipid metabolism in kidney disease development","volume":"106","author":"Lee","year":"2024","journal-title":"Kidney Int"},{"key":"2026031808521417400_bib60","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.tem.2012.06.006","article-title":"Transcriptional integration of mitochondrial biogenesis","volume":"23","author":"Scarpulla","year":"2012","journal-title":"Trends Endocrinol Metabol"},{"key":"2026031808521417400_bib61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2020.11.011","article-title":"The nuclear receptor ESRRA protects from kidney disease by coupling metabolism and differentiation","volume":"33","author":"Dhillon","year":"2021","journal-title":"Cell Metab"},{"key":"2026031808521417400_bib62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.semnephrol.2018.01.003","article-title":"The role of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) in kidney disease","volume":"38","author":"Li","year":"2018","journal-title":"Semin Nephrol"},{"key":"2026031808521417400_bib63","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cmet.2019.08.003","article-title":"Mitochondrial damage and activation of the STING pathway lead to renal inflammation and fibrosis","volume":"30","author":"Chung","year":"2019","journal-title":"Cell Metab"},{"key":"2026031808521417400_bib64","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.cmet.2022.09.026","article-title":"Comprehensive single-cell transcriptional profiling defines shared and unique epithelial injury responses during kidney fibrosis","volume":"34","author":"Li","year":"2022","journal-title":"Cell Metab"},{"key":"2026031808521417400_bib65","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2172-11-58","article-title":"CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe\u2212\/\u2212 mice","volume":"11","author":"Kolbus","year":"2010","journal-title":"BMC Immunol"},{"key":"2026031808521417400_bib66","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.cell.2015.10.068","article-title":"CD5L\/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"2026031808521417400_bib67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/CIRCULATIONAHA.110.006411","article-title":"Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia","volume":"124","author":"Maganto-Garcia","year":"2011","journal-title":"Circulation"},{"key":"2026031808521417400_bib68","doi-asserted-by":"publisher","first-page":"155452","DOI":"10.1016\/j.cyto.2021.155452","article-title":"Altered Th17\/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy","volume":"141","author":"Motavalli","year":"2021","journal-title":"Cytokine"},{"key":"2026031808521417400_bib69","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s10020-024-01014-3","article-title":"HFD aggravated the arthritis and atherosclerosis by altering the intestinal status and gut microbiota","volume":"30","author":"Shi","year":"2024","journal-title":"Mol Med"},{"key":"2026031808521417400_bib70","doi-asserted-by":"publisher","first-page":"101969","DOI":"10.1016\/j.mcp.2024.101969","article-title":"The effectiveness of ruxolitinib and cyclophosphamide combination on T helper 17 and regulatory T cells in rat experimental membranous glomerulonephritis","volume":"76","author":"Iranzad","year":"2024","journal-title":"Mol Cell Probes"},{"key":"2026031808521417400_bib71","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1161\/ATVBAHA.117.310678","article-title":"Follicular B cells promote atherosclerosis via T cell-mediated differentiation into plasma cells and secreting pathogenic immunoglobulin G","volume":"38","author":"Tay","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026031808521417400_bib72","doi-asserted-by":"publisher","first-page":"12044","DOI":"10.1111\/jcmm.15836","article-title":"Altered frequency of peripheral B-cell subsets and their correlation with disease activity in patients with systemic lupus erythematosus: a comprehensive analysis","volume":"24","author":"Peng","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2026031808521417400_bib73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cell.2008.04.052","article-title":"LXR signaling couples sterol metabolism to proliferation in the acquired immune response","volume":"134","author":"Bensinger","year":"2008","journal-title":"Cell"},{"key":"2026031808521417400_bib74","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.immuni.2016.11.008","article-title":"Cholesterol accumulation in CD11c(+) immune cells is a causal and targetable factor in autoimmune disease","volume":"45","author":"Ito","year":"2016","journal-title":"Immunity"},{"key":"2026031808521417400_bib75","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.cmet.2017.04.005","article-title":"Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity","volume":"25","author":"Westerterp","year":"2017","journal-title":"Cell Metab"},{"key":"2026031808521417400_bib76","doi-asserted-by":"publisher","first-page":"650856","DOI":"10.3389\/fimmu.2021.650856","article-title":"Dietary supplementation with eicosapentaenoic acid inhibits plasma cell differentiation and attenuates lupus autoimmunity","volume":"12","author":"Kobayashi","year":"2021","journal-title":"Fron. Immunol"},{"key":"2026031808521417400_bib77","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamadermatol.2022.5182","article-title":"Association of rituximab with risk of long-term cardiovascular and metabolic outcomes in patients with pemphigus","volume":"159","author":"Kridin","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026031808521417400_bib78","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.4049\/jimmunol.1000033","article-title":"Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis","volume":"185","author":"Kyaw","year":"2010","journal-title":"J Immunol"},{"key":"2026031808521417400_bib79","doi-asserted-by":"publisher","first-page":"112769","DOI":"10.1016\/j.intimp.2024.112769","article-title":"B cell dysregulation and depletion therapy in primary membranous nephropathy: prospects and potential challenges","volume":"140","author":"Wu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026031808521417400_bib80","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","article-title":"The role of complement in membranous nephropathy","volume":"33","author":"Ma","year":"2013","journal-title":"Semin Nephrol"},{"key":"2026031808521417400_bib81","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2147\/IJGM.S407073","article-title":"Lectin complement pathway activation is associated with massive proteinuria in PLA2R-positive membranous nephropathy: a retrospective study","volume":"16","author":"Li","year":"2023","journal-title":"Int J Gen Med"},{"key":"2026031808521417400_bib82","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.4049\/jimmunol.164.5.2281","article-title":"Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease","volume":"164","author":"Matsushita","year":"2000","journal-title":"J Immunol"},{"key":"2026031808521417400_bib83","doi-asserted-by":"publisher","first-page":"e38990","DOI":"10.1097\/MD.0000000000038990","article-title":"A review of progress on complement and primary membranous nephropathy","volume":"103","author":"Yu","year":"2024","journal-title":"Medicine"},{"key":"2026031808521417400_bib84","doi-asserted-by":"publisher","first-page":"27266","DOI":"10.1038\/s41598-024-78325-2","article-title":"Prognostic value of serum complement cleavage factor Bb in idiopathic membranous nephropathy and establishment of nomogram model","volume":"14","author":"Wen","year":"2024","journal-title":"Sci Rep"},{"key":"2026031808521417400_bib85","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1161\/01.ATV.0000127302.24266.40","article-title":"Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-\/- low-density lipoprotein receptor-\/- mice","volume":"24","author":"Persson","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026031808521417400_bib86","doi-asserted-by":"publisher","first-page":"112224","DOI":"10.1016\/j.biopha.2021.112224","article-title":"The pleotropic effects of fluvastatin on complement-mediated T-cell activation in hypercholesterolemia","volume":"143","author":"Nyambuya","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2026031808521417400_bib87","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejim.2024.02.015","article-title":"The complement system in the pathogenesis and progression of kidney diseases: what doesn\u2019t kill you makes you older","volume":"124","author":"Stea","year":"2024","journal-title":"Eur J Int Med"},{"key":"2026031808521417400_bib88","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00467-018-4042-z","article-title":"The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?","volume":"34","author":"Michels","year":"2019","journal-title":"Pediatr Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag032\/66844042\/sfag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/3\/sfag032\/66844042\/sfag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/3\/sfag032\/66844042\/sfag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:56:00Z","timestamp":1773838560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag032\/8471540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag032","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,10]]},"article-number":"sfag032"}}